AUTHORS: Sabrina H Han, BHS; Rachel Safeek, MD, Kyle Ockerman, BS, Nhan Trieu, BS, Patricia Mars, MD, Audrey Klenke, MD, Heather Furnas, MD, Sarah Sorice-Virk, MD
SUMMARY: The study analyzes public interest in the off-label use of glucagon-like peptide 1 (GLP-1) agonists, particularly Ozempic, for cosmetic weight loss through Google Trends data. It reveals a significant increase in search queries related to Ozempic, indicating rising public awareness and interest in its weight loss potential beyond its primary diabetes treatment use. The findings suggest that demand for non-surgical weight loss solutions is growing, raising concerns about safety, efficacy, and potential regulatory implications. The study underscores the need for further research and guidance regarding off-label uses of such medications in cosmetic applications.
